Faslodex®: FDA approves increased dose

The US Food and Drug Administration has approved a change in the dosage of Faslodex® to 500 mg; previously, the approved dose was 250 mg. Faslodex is used for treatment of metastatic breast cancer following progression of disease in estrogen receptor-positive post-menopausal women who had previously received antiestrogen treatment. US FDA approval for the increase is based on the results that show a reduced risk of disease progression and also an increase in survival.

FDA Approves New Dosing for FASLODEX(R) (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women. Press release: AsraZeneca. In Market Watch. 9-10-10

5 6 7 8

© 2004-2010 Donna Peach. All rights reserved.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s